These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. Tobinai K; Klein C; Oya N; Fingerle-Rowson G Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361 [TBL] [Abstract][Full Text] [Related]
46. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity. Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740 [TBL] [Abstract][Full Text] [Related]
47. Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Bello C; Veliz M; Pinilla-Ibarz J Expert Rev Clin Immunol; 2011 May; 7(3):295-300. PubMed ID: 21595596 [TBL] [Abstract][Full Text] [Related]
48. Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies. Smolewski P; Robak P; Cebula-Obrzut B; Misiewicz M; Mędra A; Majchrzak A; Witkowska M; Stromatt S; Robak T Eur J Cancer; 2014 Oct; 50(15):2677-84. PubMed ID: 25154027 [TBL] [Abstract][Full Text] [Related]
49. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278 [TBL] [Abstract][Full Text] [Related]
50. Role of ofatumumab in treatment of chronic lymphocytic leukemia. Veliz M; Pinilla-Ibarz J J Blood Med; 2011; 2():71-7. PubMed ID: 22287865 [TBL] [Abstract][Full Text] [Related]
54. The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies. Markovič T; Podgornik H; Avsec D; Nabergoj S; Mlinarič-Raščan I Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163524 [TBL] [Abstract][Full Text] [Related]
55. Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement. Okroj M; Eriksson I; Österborg A; Blom AM Med Oncol; 2013 Dec; 30(4):759. PubMed ID: 24198205 [TBL] [Abstract][Full Text] [Related]
57. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJ; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Osterborg A; J Clin Oncol; 2010 Apr; 28(10):1749-55. PubMed ID: 20194866 [TBL] [Abstract][Full Text] [Related]
58. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Da Roit F; Engelberts PJ; Taylor RP; Breij EC; Gritti G; Rambaldi A; Introna M; Parren PW; Beurskens FJ; Golay J Haematologica; 2015 Jan; 100(1):77-86. PubMed ID: 25344523 [TBL] [Abstract][Full Text] [Related]
59. Effect of alemtuzumab on neoplastic B cells. Golay J; Manganini M; Rambaldi A; Introna M Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398 [TBL] [Abstract][Full Text] [Related]
60. The use of ofatumumab in the treatment of B-cell malignancies. Soe ZN; Allsup D Future Oncol; 2017 Dec; 13(29):2611-2628. PubMed ID: 28850252 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]